deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT03400176

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy

Sponsor: Novartis Pharmaceuticals

Conditions Chronic Lymphocytic Leukemia (CLL)
Interventions VAY736 ibrutinib
Updated 24 times since 2018 Last updated: May 14, 2025 Started: Apr 9, 2018 Primary completion: Sep 29, 2023 Completion: Sep 29, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business reasons

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

Other Chronic Lymphocytic Leukemia (CLL) trials with similar outcome

Browse all Chronic Lymphocytic Leukemia (CLL) trials

This PHASE1 trial investigates Chronic Lymphocytic Leukemia (CLL) and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 24 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2019 · 13 months · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Mar 2023 · 9 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Dec 2023 · 5 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

24 versions recorded

  1. Jun 2025 — Present [monthly]

    Terminated PHASE1

  2. Oct 2024 — Jun 2025 [monthly]

    Terminated PHASE1

  3. Sep 2024 — Oct 2024 [monthly]

    Terminated PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  5. Dec 2023 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

▶ Show 19 earlier versions

  1. Jul 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Apr 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

  4. Jun 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Jan 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  6. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  7. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  8. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  9. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  10. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  11. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  12. Jul 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

  13. Mar 2020 — Jul 2020 [monthly]

    Recruiting PHASE1

  14. Nov 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  15. Oct 2018 — Nov 2019 [monthly]

    Recruiting PHASE1

  16. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  17. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  18. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE1

  19. Feb 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations